Sabinsa has been granted a US patent for the company’s shelf-stable probiotic LactoSpore in combination with cranberry seed fibres
The granted patent (US 9717766) discloses a method of increasing the viable colony count of Bacillus coagulans MTCC 5856 in a synbiotic composition containing natural plant fibres from Vaccinium oxycoccos (cranberry).
The cranberry fibres in this composition were observed to increase the viable count of Bacillus coagulans MTCC 5856.
This combination product is sold under the name LactoCran, with the cranberry seed fibre components supplied by Fruit d'Or Nutraceuticals of Quebec, Canada.
LactoCran provides support for healthy gut and digestive health. The non-lactose, diary free, non-GMO combination works well in sports nutrition supplements as it contains a rich composition of 16 essential amino acids and 8 branch chain amino acids.
This patent, along with the previously granted patent for the management of irritable bowel syndrome, is expected to boost LactoSpore’s popularity and market value.
LactoSpore is a GRAS probiotic containing Bacillus coagulans MTCC 5856, which is lactose-free and non-GMO.
This exceptional probiotic is room temperature stable and does not require refrigeration, ensuring a long product shelf-life.
Because of its ability to withstand high heat, LactoSpore has been included in functional baked goods. Clinically studied LactoSpore can be used in a variety of food and dietary supplements for maintaining gut health and good microbiota.